Muscle News and Research

RSS

New synthetic small molecules could treat obesity, diabetes and sleep disorders

Scientists from the Florida campus of The Scripps Research Institute have synthesized a pair of small molecules that dramatically alter the core biological clock in animal models, highlighting the compounds' potential effectiveness in treating a remarkable range of disorders-including obesity, diabetes, high cholesterol, and serious sleep disorders.

30 Mar 2012

Sitting more than four hours a day could raise risk of dying early: Study

According to Australian researchers spending less time sitting could boost longevity. Their study of more than 220,000 NSW residents found the longer you spend sitting down the greater your risk of dying early, even if you otherwise do regular exercise.

29 Mar 2012

FDA extends review period for Almirall and Forest Labs' aclidinium bromide NDA

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

Researchers describe unexpected role of p75NTR in type 2 diabetes

Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance-the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes. This breakthrough points to a new way to potentially treat or forestall type 2 diabetes, a rapidly growing global health problem.

29 Mar 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

New MRI method to test effectiveness of baking soda against breast cancer

A University of Arizona study that looks to improve the way doctors can measure the effectiveness of drinking baking soda to fight breast cancer has received a $2 million grant from the National Institutes of Health.

28 Mar 2012

Invasive strategy benefits patients with myotonic dystrophy type 1 neuromuscular disorder

Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.

28 Mar 2012

CABG offers higher survival rates for older adults with CHD than PCI

A new comparative effectiveness study found older adults with stable coronary heart disease (CHD) who underwent bypass surgery had better long-term survival rates than those who underwent a non-surgical procedure to improve blood flow to the heart muscle, also called revascularization.

28 Mar 2012

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or “bad” cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.

27 Mar 2012

Boniva generics receive FDA approval for treatment, prevention of osteoporosis

The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.

27 Mar 2012

Sientra receives FDA approval for new silicone gel-filled breast implant

Today, the U.S. Food and Drug Administration approved a silicone gel-filled breast implant manufactured by Sientra Inc. to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age.

27 Mar 2012

UK researcher receives IOF-Servier Young Investigator Research Grant

The IOF-Servier Young Investigator Research Grant has been awarded to Dr Mark Edwards, clinical research fellow at the MRC Lifecourse Epidemiology Unit at Southhampton General Hospital in the UK.

27 Mar 2012

Tips to prevent tick-borne diseases

Spring has only just arrived, but tick season is well under way. Physicians are seeing new cases of tick-borne illness several weeks earlier than usual, likely because a mild winter in much of the country made life easier for ticks and their offspring. That means it's time for gardeners, hikers, pet owners and others who spend time outdoors to take steps to protect themselves -- and to watch for symptoms of tick-borne illness if they do come in contact with the tiny bloodsuckers.

27 Mar 2012

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology.

27 Mar 2012

Study clarifies conflicting reports for clot aspiration and abciximab administration

The anti-platelet drug abciximab, delivered directly to lesions caused by a heart attack, significantly decreased damage to the heart muscle in high-risk patients while clot aspiration showed no impact, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

From Medtronic 27 Mar 2012

ACS symposium focuses on biomimetics

Combining the secrets that enable water striders to walk on water and give wood its lightness and great strength has yielded an amazing new material so buoyant that, in everyday terms, a boat made from 1 pound of the substance could carry five kitchen refrigerators, about 1,000 pounds.

27 Mar 2012

Bolus intracoronary abciximab reduces infarct size in high-risk patients with STEMI

Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.

27 Mar 2012

Mayo Clinic researchers join expedition to Everest

It's a natural laboratory for studying heart disease, lung problems, muscle loss, sleeping disorders and new medical technologies. It's also the highest mountain in the world. Mount Everest's extreme altitude puts climbers under the same conditions experienced by patients suffering from heart disease, obesity or advanced age. To take advantage of that, Mayo Clinic researchers are joining an expedition to Everest with National Geographic, The North Face and Montana State University.

26 Mar 2012

Novel device for measuring pelvic floor muscle strength

It is estimated that urine loss affects 30% of women at some point in their lives. Despite this high incidence rate, up until now clinical evaluation of patients suffering from this problem has been based on tactile examination, a subjective procedure that is not carried out in a consistent way by different medical professionals.

26 Mar 2012